ストックスクリーナーアプリを入手
2.85
5.00%
-0.15
アフターアワーズ：
2.98
0.13
+4.56%
前日終値:
$3.00
開ける：
$3.07
24時間の取引高:
1.52M
Relative Volume:
1.68
時価総額：
$226.95M
収益：
-
当期純損益:
$-79.79M
株価収益率:
-2.3709
EPS:
-1.2021
ネットキャッシュフロー:
$-67.24M
1週間 パフォーマンス:
+4.78%
1か月 パフォーマンス:
+28.38%
6か月 パフォーマンス:
+11.76%
1年 パフォーマンス:
-19.94%
1日の値動き範囲:
$2.83
$3.07
1週間の範囲:
$2.655
$3.10
52週間の値動き範囲:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
名前
Eledon Pharmaceuticals Inc
セクター
電話
949-238-8090
住所
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
2.85 | 238.89M | 0 | -79.79M | -67.24M | -1.2021 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-18 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Guggenheim | Buy |
| 2022-05-13 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 開始されました | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc (ELDN) 最新ニュース
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - The Manila Times
Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs - TradingView
Eledon (NASDAQ: ELDN) 2025 results show higher R&D spend and cash - Stock Titan
Tegoprubart data and new orphan status headline Eledon (NASDAQ: ELDN) 2025 update - Stock Titan
Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings - TipRanks
ELDN PE Ratio & Valuation, Is ELDN Overvalued - Intellectia AI
Eledon reports insulin independence in islet transplant trial By Investing.com - Investing.com Australia
Leerink Maintains Outperform on ELDN (Eledon Pharmaceuticals) March 16, 2026 - Meyka
Eledon Pharmaceuticals (ELDN) Presents Promising Diabetes Trial Results - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative - Seeking Alpha
Leerink Partners reiterates Outperform on Eledon stock at $5 By Investing.com - Investing.com Canada
Eledon announces updated data from investigator-initiated islet transplant trial of tegoprubart in patients with type 1 diabetes at UChicago Medicine - marketscreener.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine - Bitget
Eledon reports insulin independence in islet transplant trial - Investing.com
Eledon Pharmaceuticals Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Experimental transplant drug lets 10 diabetes patients stop insulin - Stock Titan
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals at Leerink Conference: Strategic Insights on Transplantation By Investing.com - Investing.com Canada
ELDN: Tegoprubart advances with strong safety data, phase 3 plans, and cash runway into Q2 2025 - TradingView
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Eledon's Tegoprubart Gets FDA's Orphan Drug Designation In Liver Transplantation; Stock Up - RTTNews
Eledon Pharma wins FDA orphan status for lead asset (ELDN) - Seeking Alpha
Eledon Pharmaceuticals (ELDN) Gains FDA Orphan Drug Status for T - GuruFocus
FDA gives rare-disease status to drug aiming to protect liver transplants - Stock Titan
NewcelX and Eledon partner for NCEL-101 programme - Yahoo Finance
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation - Bitget
Newcelx partners with Eledon to advance NCEL-101 - BioWorld MedTech
NewcelX, Eledon Partner to Advance a Potential Functional Cure for Type 1 Diabetes - Contract Pharma
Eledon Pharmaceuticals (ELDN) Enters Research Partnership to Com - GuruFocus
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes - TradingView
NewcelX partners with Eledon on type 1 diabetes therapy - Investing.com UK
Eledon’s Transplant Drug Is Heading Toward A Phase 3 Moment - Finimize
ELDN SEC FilingsEledon Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
What Makes Eledon Pharmaceuticals (ELDN) a New Buy Stock - MSN
Jobs Data: Is Eledon Pharmaceuticals Inc. stock a top pick in earnings seasonLong Setup & Daily Technical Forecast Reports - Naître et grandir
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference - Sahm
Targets Report: Is Eledon Pharmaceuticals Inc backed by strong institutional buyingJuly 2025 Institutional & Risk Controlled Swing Alerts - baoquankhu1.vn
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Aug Gainers: Whats Eledon Pharmaceuticals Incs historical returnBond Market & Daily Stock Trend Watchlist - baoquankhu1.vn
ELDN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Arkansas woman participates in clinical trial to cure type one diabetes - KARK
What makes Eledon Pharmaceuticals Inc. stock attractive todayGlobal Markets & High Accuracy Trade Signal Alerts - mfd.ru
Will Eledon Pharmaceuticals Inc. stock deliver shareholder valueWeekly Investment Summary & Long-Term Safe Investment Ideas - mfd.ru
What’s the beta of Eledon Pharmaceuticals Inc. stock2025 Year in Review & Consistent Growth Equity Picks - mfd.ru
Can Eledon Pharmaceuticals Inc. expand its profit marginsGap Down & Free High Return Stock Watch Alerts - mfd.ru
Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference - MarketBeat
Eledon Pharmaceuticals at Guggenheim Summit: Tegoprubart’s Promising Path By Investing.com - Investing.com Canada
Eledon Pharmaceuticals Inc (ELDN) 財務データ
収益
当期純利益
現金流量
EPS
1.20%
0.06%
大文字化:
|
ボリューム (24 時間):